FLF Launches a Patient Education Partnership to Expand Patient Outreach and Accelerate Early Identification of People with Undiagnosed Nonalcoholic Steatohepatitis  

BOISE, ID; Dec 07, 2020 ― The Fatty Liver Foundation (FLF) announced today it is launching a new patient education partnership, in collaboration with Fibronostics, to meet the urgent need for early screening, identification, and intervention for people at-risk of developing nonalcoholic steatohepatitis. FLF and Fibronostics will work toward a shared mission of facilitating access to non-invasive tests that can help identify those at-risk of developing NASH as early as possible.

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that describes a spectrum of conditions ranging from non-alcoholic fatty liver to the more aggressive nonalcoholic steatohepatitis (NASH). NASH is a serious condition and can cause scarring of the liver, which leads to cirrhosis, as well as metabolic complications making it a unique medical condition requiring complex care. Comorbidities, such as metabolic syndrome, obesity and NASH, increase the risk factor and severity for patients with the COVID-19 virus.

Since NASH is asymptomatic until advanced disease, many patients are only identified at advanced stages. One of FLF’s core priorities is to educate people at-risk for NASH and facilitate access to early screening, diagnosis, and care that can save lives.

“We know that with NAFLD and NASH, early screening and interventions before the onset of symptoms improve long-term outcomes,” said Wayne Eskridge, CEO and Co-Founder of Fatty Liver Foundation. “This new partnership will strengthen and accelerate FLF’s efforts to enable transformative change by expanding screening options for early identification of asymptomatic, undiagnosed NASH and educating patients on the lifestyle changes as well as other interventions needed to halt or minimize disease progression.”

“Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and a lack of pharmacological agents with proven efficacy. LIVERFASt™ aids healthcare providers with diagnosis information on all three lesions, enabling a more proactive management of patients with NAFLD, T2DM and NASH,” said Roni Amiel, CEO of Fibronostics.

# # #

 About the Fatty Liver Foundation

The Fatty Liver Foundation is a non-profit patient organization dedicated to improving the identification, diagnosis, treatment and support of people living with fatty liver, NAFLD or NASH through awareness, screening, education and patient outreach. FLF’s goal is to improve the lives of both asymptomatic and diagnosed patients by raising awareness, developing wellness screening, educating patients, and championing the development of a responsive support systems for individuals of the growing epidemic of fatty liver disease. Connect with us on www.fattyliverfoundation.org, Facebook, and Twitter (@LiverSaver). 

 About Fibronostics

Fibronostics is a global diagnostics company, shaping the future of non-invasive diagnostics with artificial intelligence providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on screening, progression and prognosis of liver & kidney disease, and other chronic conditions. The company is incorporated in Singapore & New York and is currently commercialized in North America, Asia, Europe and LATAM. Fibronostics a SPRIM portfolio company with a pedigree in worldwide health innovation, research & consulting. For more information, please visit www.fibronostics.com.